What is Enanta Pharmaceuticals' operating income?

Enanta Pharmaceuticals' total operating income in 2025 was -$85.35 million, based on the following breakdown: Total Gross Profit: $65.32 million Total Operating Expenses: $150.67 million

Enanta Pharmaceuticals (ENTA) Financials

$15.11 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$14.80 -0.31 (-2.08%)

As of 07/2/2026 04:57 PM Eastern

Compare

Annual Income Statements for Enanta Pharmaceuticals

This table shows Enanta Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	9/30/2015	9/30/2016	9/30/2017	9/30/2018	9/30/2019	9/30/2020	9/30/2021	9/30/2022	9/30/2023	9/30/2024	9/30/2025
Net Income / (Loss) Attributable to Common Shareholders	79	22	18	72	46	-36	-79	-122	-134	-116	-82
Consolidated Net Income / (Loss)	79	22	18	72	46	-36	-79	-122	-134	-116	-82
Net Income / (Loss) Continuing Operations	79	22	18	72	46	-36	-79	-122	-134	-116	-82
Total Pre-Tax Income	125	33	27	93	46	-35	-108	-122	-131	-118	-84
Total Operating Income	124	31	25	88	37	-42	-110	-124	-137	-122	-85
Total Gross Profit	161	88	103	207	205	122	97	86	79	68	65
Total Revenue	161	88	103	207	205	122	97	86	79	68	65
Operating Revenue	161	88	103	207	205	122	97	86	79	68	65
Total Cost of Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Operating Expenses	37	57	78	118	168	164	207	210	216	189	151
Selling, General & Admin Expense	14	17	21	23	26	27	33	45	53	58	44
Research & Development Expense	23	40	57	95	142	137	174	165	164	131	107
Total Other Income / (Expense), net	1.31	1.72	2.33	4.79	8.82	6.62	1.99	1.66	6.21	3.90	1.80
Interest Expense	0.01	-	-	-	-	-	0.00	0.00	5.15	11	7.68
Interest & Investment Income	0.97	1.69	2.49	4.85	8.82	6.47	2.02	1.57	11	15	9.44
Other Income / (Expense), net	0.35	0.03	-0.16	-0.06	0.00	0.15	-0.03	0.08	0.00	0.07	0.04
Income Tax Expense	46	11	9.24	21	-0.83	1.15	-29	-0.43	2.82	-1.74	-1.66
Basic Earnings per Share	$4.23	$1.14	$0.93	$3.74	$2.37	($1.81)	($3.92)	($5.91)	($6.38)	($5.48)	($3.84)
Weighted Average Basic Shares Outstanding	18.67M	18.93M	19.07M	19.26M	19.58M	19.94M	20.17M	20.60M	20.97M	21.16M	21.34M
Diluted Earnings per Share	$4.09	$1.13	$0.91	$3.48	$2.21	($1.81)	($3.92)	($5.91)	($6.38)	($5.48)	($3.84)
Weighted Average Diluted Shares Outstanding	19.30M	19.22M	19.41M	20.65M	20.97M	19.94M	20.17M	20.60M	20.97M	21.16M	21.34M
Weighted Average Basic & Diluted Shares Outstanding	18.70M	19M	19M	19.20M	19.73M	20.08M	20.32M	20.80M	21.06M	21.19M	28.86M

This table shows Enanta Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026	Q2 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	12/31/2025	3/31/2026
Net Income / (Loss) Attributable to Common Shareholders	-28	-33	-31	-23	-29	-22	-23	-18	-12	-13
Consolidated Net Income / (Loss)	-28	-33	-31	-23	-29	-22	-23	-18	-12	-13
Net Income / (Loss) Continuing Operations	-28	-33	-31	-23	-29	-22	-23	-18	-12	-13
Total Pre-Tax Income	-30	-34	-32	-23	-29	-23	-24	-18	-12	-13
Total Operating Income	-31	-35	-33	-24	-30	-24	-25	-19	-11	-12
Total Gross Profit	19	18	17	18	15	17	15	18	19	17
Total Revenue	19	18	17	18	15	17	15	18	19	17
Operating Revenue	19	18	17	18	15	17	15	18	19	17
Total Cost of Revenue	-	0.00	0.00	0.00	-	0.00	0.00	0.00	0.00	0.00
Total Operating Expenses	50	53	50	42	44	41	39	37	30	29
Selling, General & Admin Expense	14	17	14	13	14	13	11	10.00	9.01	9.57
Research & Development Expense	36	36	36	29	31	28	28	27	21	19
Total Other Income / (Expense), net	1.51	0.86	1.25	1.13	0.67	0.84	0.58	0.67	-0.66	-1.23
Interest Expense	3.15	3.44	2.56	2.36	2.58	1.96	1.71	1.62	3.08	3.32
Interest & Investment Income	4.66	4.30	3.81	3.49	3.18	2.80	2.29	2.29	2.42	2.08
Income Tax Expense	-1.41	-0.62	-0.36	-0.40	-0.36	-0.42	-1.31	0.03	0.02	0.01
Basic Earnings per Share	($1.34)	($1.58)	($1.47)	($1.07)	($1.36)	($1.05)	($1.06)	($0.85)	($0.42)	($0.45)
Weighted Average Basic Shares Outstanding	20.97M	21.09M	21.17M	21.18M	21.16M	21.24M	21.36M	21.38M	28.75M	29.04M
Diluted Earnings per Share	($1.34)	($1.58)	($1.47)	($1.07)	($1.36)	($1.05)	($1.06)	($0.85)	($0.42)	($0.45)
Weighted Average Diluted Shares Outstanding	20.97M	21.09M	21.17M	21.18M	21.16M	21.24M	21.36M	21.38M	28.75M	29.04M
Weighted Average Basic & Diluted Shares Outstanding	21.06M	21.33M	21.18M	21.19M	21.19M	-	21.38M	21.38M	29.02M	29.08M

This table details how cash moves in and out of Enanta Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	9/30/2015	9/30/2016	9/30/2017	9/30/2018	9/30/2019	9/30/2020	9/30/2021	9/30/2022	9/30/2023	9/30/2024	9/30/2025
Net Change in Cash & Equivalents	-8.97	-5.15	49	-1.77	-13	36	-30	-9.85	41	-48	-5.54
Net Cash From Operating Activities	77	36	53	29	71	7.09	-70	-85	-103	-79	-19
Net Cash From Continuing Operating Activities	77	36	53	29	71	7.09	-70	-85	-103	-79	-19
Net Income / (Loss) Continuing Operations	79	22	18	72	46	-36	-79	-122	-134	-116	-82
Consolidated Net Income / (Loss)	79	22	18	72	46	-36	-79	-122	-134	-116	-82
Depreciation Expense	0.64	1.66	2.14	2.52	3.26	3.64	3.33	2.97	2.37	2.34	4.59
Amortization Expense	2.24	1.51	0.70	-0.84	-4.34	0.30	2.12	1.17	-2.86	-1.14	0.50
Non-Cash Adjustments To Reconcile Net Income	0.60	7.09	12	16	18	16	17	27	23	29	23
Changes in Operating Assets and Liabilities, net	-5.80	3.88	20	-60	8.35	24	-13	5.72	8.02	7.13	34
Net Cash From Investing Activities	-88	-44	-4.57	-35	-87	20	37	55	-54	58	40
Net Cash From Continuing Investing Activities	-88	-44	-4.57	-35	-87	20	37	55	-54	58	40
Purchase of Property, Plant & Equipment	-2.34	-4.74	-2.51	-2.98	-5.42	-1.45	-0.75	-2.13	-9.06	-18	-13
Purchase of Investments	-196	-192	-251	-293	-549	-339	-307	-171	-373	-307	-210
Sale and/or Maturity of Investments	111	154	249	261	468	360	345	228	329	383	263
Net Cash From Financing Activities	2.54	2.71	1.02	4.41	2.57	8.98	3.08	20	198	-28	-27
Net Cash From Continuing Financing Activities	2.54	2.71	1.02	4.41	2.57	8.98	3.08	20	198	-28	-27
Repayment of Debt	-	-0.07	-0.07	-0.08	-0.09	-	0.00	0.00	-0.33	0.00	0.00
Other Financing Activities, net	2.54	2.77	0.01	-1.76	-4.19	8.98	3.08	20	198	-28	-27
Cash Interest Paid	-	-	-	-	-	-	-	0.00	1.99	12	8.79
Cash Income Taxes Paid	40	13	1.59	26	13	0.11	0.03	0.00	4.90	0.24	0.11

This table details how cash moves in and out of Enanta Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Change in Cash & Equivalents	-9.79	-45	24	-28	1.46	47	-25	-15	-13	5.14	-2.51
Net Cash From Operating Activities	-22	-25	-29	-15	-10	-17	-13	18	-6.49	-12	-7.16
Net Cash From Continuing Operating Activities	-22	-25	-29	-15	-10	-17	-13	18	-6.49	-12	-7.16
Net Income / (Loss) Continuing Operations	-28	-33	-31	-23	-29	-22	-23	-18	-19	-12	-13
Consolidated Net Income / (Loss)	-28	-33	-31	-23	-29	-22	-23	-18	-19	-12	-13
Depreciation Expense	0.67	0.64	0.62	0.59	0.48	0.89	1.20	1.21	1.28	1.23	1.21
Amortization Expense	-0.06	0.27	0.03	-0.24	-1.20	0.63	0.82	0.01	-0.96	0.02	0.30
Non-Cash Adjustments To Reconcile Net Income	-3.50	9.31	4.83	4.83	15	6.83	6.87	7.23	7.06	1.58	4.76
Changes in Operating Assets and Liabilities, net	9.40	-1.81	-2.92	2.70	3.71	-2.86	0.27	27	4.83	-2.59	-0.34
Net Cash From Investing Activities	12	-13	59	-6.35	19	69	-4.37	-26	2.30	-47	12
Net Cash From Continuing Investing Activities	12	-13	59	-6.35	19	69	-4.37	-26	2.30	-47	12
Purchase of Property, Plant & Equipment	-1.37	-0.79	-1.67	-6.54	-8.95	-8.75	-2.54	-0.16	-1.46	-0.14	-0.02
Purchase of Investments	-106	-147	-65	-95	0.00	0.00	-55	-86	-69	-149	-42
Sale and/or Maturity of Investments	119	135	126	95	28	78	53	60	72	101	54
Net Cash From Financing Activities	-0.02	-7.35	-6.41	-6.65	-7.22	-4.99	-6.89	-6.42	-8.32	64	-7.30
Net Cash From Continuing Financing Activities	-0.02	-7.35	-6.41	-6.65	-7.22	-4.99	-6.89	-6.42	-8.32	64	-7.30
Other Financing Activities, net	-0.02	-7.35	-6.41	-6.65	-7.22	-4.99	-6.89	-6.42	-8.32	-5.81	-7.30
Cash Interest Paid	1.99	3.14	3.43	2.61	2.52	3.01	2.47	1.71	1.61	2.38	3.07

This table presents Enanta Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	9/30/2015	9/30/2016	9/30/2017	9/30/2018	9/30/2019	9/30/2020	9/30/2021	9/30/2022	9/30/2023	9/30/2024	9/30/2025
Total Assets	246	281	327	414	490	486	439	375	462	377	281
Total Current Assets	171	232	238	380	402	437	319	312	423	300	204
Cash & Equivalents	22	17	66	64	51	87	57	44	85	37	32
Short-Term Investments	123	194	158	245	284	300	187	205	285	211	157
Accounts Receivable	16	13	11	67	51	23	24	20	8.61	6.65	6.88
Prepaid Expenses	8.27	9.23	3.54	4.45	15	14	14	13	13	12	8.59
Current Deferred & Refundable Income Taxes	1.45	-	-	-	-	-	-	29	31	32	0.00
Plant, Property, & Equipment, net	5.89	8.00	8.05	8.37	11	8.60	5.94	6.17	12	33	35
Total Noncurrent Assets	69	41	81	25	77	41	114	58	28	44	41
Long-Term Investments	64	32	70	16	65	33	108	29	0.00	0.00	0.00
Other Noncurrent Operating Assets	-	-	-	0.09	0.09	7.11	4.80	24	28	44	41
Total Liabilities & Shareholders' Equity	246	281	327	414	490	486	439	375	462	377	281
Total Liabilities	9.86	11	25	21	27	31	39	54	246	248	216
Total Current Liabilities	6.70	7.89	21	16	23	24	36	30	63	58	49
Accounts Payable	1.54	3.38	3.71	4.75	6.69	5.74	9.54	6.00	4.10	8.00	1.95
Accrued Expenses	3.96	4.51	7.97	9.89	16	14	22	21	53	48	43
Other Current Liabilities	-	-	-	-	0.00	4.26	4.20	2.89	5.28	1.52	3.15
Total Noncurrent Liabilities	3.15	3.45	3.98	4.52	4.73	6.40	3.19	24	183	190	167
Other Noncurrent Operating Liabilities	3.15	3.45	3.98	4.52	4.73	6.40	3.19	24	183	190	167
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	236	270	302	394	462	456	399	321	217	129	65
Total Preferred & Common Equity	236	270	302	394	462	456	399	321	217	129	65
Total Common Equity	236	270	302	394	462	456	399	321	217	129	65
Common Stock	230	242	256	277	299	327	351	398	425	452	470
Retained Earnings	5.98	28	45	117	164	128	49	-73	-207	-323	-405
Accumulated Other Comprehensive Income / (Loss)	0.03	0.02	-0.11	-0.40	0.15	0.84	-0.38	-3.72	-1.17	0.30	-0.34

This table presents Enanta Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2024	Q2 2024	Q3 2024	Q2 2025	Q3 2025	Q1 2026	Q2 2026
Period end date	12/31/2024	3/31/2024	6/30/2024	3/31/2025	6/30/2025	12/31/2025	3/31/2026
Total Assets	349	414	399	323	301	330	315
Total Current Assets	268	351	287	243	223	199	178
Cash & Equivalents	84	64	36	60	45	37	35
Short-Term Investments	132	237	194	133	159	148	129
Accounts Receivable	7.72	7.76	8.18	6.79	8.33	8.49	7.81
Prepaid Expenses	11	11	15	8.86	10	4.34	6.81
Current Deferred & Refundable Income Taxes	32	32	32	34	0.02	-	0.02
Plant, Property, & Equipment, net	37	15	25	38	37	34	33
Total Noncurrent Assets	43	47	87	43	42	97	103
Long-Term Investments	-	-	43	-	-	56	63
Other Noncurrent Operating Assets	43	43	45	43	42	40	40
Total Liabilities & Shareholders' Equity	349	414	399	323	301	330	315
Total Liabilities	237	247	250	229	222	203	198
Total Current Liabilities	49	55	58	46	45	45	46
Accounts Payable	4.73	6.73	11	4.76	3.55	1.89	4.36
Accrued Expenses	43	44	45	39	39	40	38
Other Current Liabilities	1.01	3.58	2.43	2.20	2.39	3.29	3.76
Total Noncurrent Liabilities	188	193	192	184	177	158	152
Other Noncurrent Operating Liabilities	188	193	192	184	177	158	152
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	112	166	149	94	79	127	117
Total Preferred & Common Equity	112	166	149	94	79	127	117
Total Common Equity	112	166	149	94	79	127	117
Common Stock	457	438	444	462	466	544	547
Retained Earnings	-345	-272	-294	-368	-386	-417	-430
Accumulated Other Comprehensive Income / (Loss)	-0.03	-0.67	-0.65	-0.22	-0.40	-0.33	-0.73

This table displays calculated financial ratios and metrics derived from Enanta Pharmaceuticals' official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	9/30/2015	9/30/2016	9/30/2017	9/30/2018	9/30/2019	9/30/2020	9/30/2021	9/30/2022	9/30/2023	9/30/2024	9/30/2025
DEI Shares Outstanding	18,713,976.00	19,035,910.00	19,090,383.00	19,377,527.00	19,681,609.00	20,072,144.00	20,214,850.00	20,724,868.00	21,055,392.00	-	21,377,923.00
DEI Adjusted Shares Outstanding	18,713,976.00	19,035,910.00	19,090,383.00	19,377,527.00	19,681,609.00	20,072,144.00	20,214,850.00	20,724,868.00	21,055,392.00	-	21,377,923.00
DEI Earnings Per Adjusted Shares Outstanding	4.22	1.14	0.93	3.71	2.36	-1.80	-3.91	-5.87	-6.36	-	-3.83
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	236.99%	-45.13%	16.48%	100.97%	-0.69%	-40.31%	-20.74%	-11.24%	-8.07%	-14.61%	-3.42%
EBITDA Growth	498.27%	-73.27%	-19.82%	229.57%	-60.36%	-205.28%	-177.42%	-14.85%	-15.11%	12.54%	33.38%
EBIT Growth	561.54%	-75.20%	-20.78%	260.94%	-58.38%	-212.93%	-164.16%	-12.92%	-10.86%	11.36%	29.85%
NOPAT Growth	130.37%	-73.75%	-21.17%	321.92%	-45.20%	-177.93%	-163.15%	-13.02%	-10.79%	11.31%	29.86%
Net Income Growth	129.37%	-72.57%	-18.26%	306.30%	-35.54%	-177.98%	-118.41%	-54.13%	-9.91%	13.28%	29.43%
EPS Growth	127.22%	-72.37%	-19.47%	282.42%	-36.49%	-181.90%	-116.57%	-50.77%	-7.95%	14.11%	29.93%
Operating Cash Flow Growth	279.96%	-53.30%	47.04%	-44.50%	144.41%	-90.08%	-1,087.53%	-21.12%	-21.67%	23.64%	75.53%
Free Cash Flow Firm Growth	346.92%	-71.53%	84.28%	-78.68%	470.67%	-107.32%	-2,630.61%	9.47%	221.28%	-223.34%	53.05%
Invested Capital Growth	58.69%	3.90%	-72.86%	823.14%	-9.30%	-42.10%	30.02%	-16.28%	-494.28%	21.67%	-3.47%
Revenue Q/Q Growth	7.90%	-1.75%	158.79%	-4.05%	-7.19%	-18.44%	-0.06%	-3.64%	-1.72%	-6.01%	0.00%
EBITDA Q/Q Growth	7.88%	-17.31%	190.86%	-20.27%	-44.02%	-194.66%	-10.87%	4.82%	-3.06%	-0.07%	0.00%
EBIT Q/Q Growth	7.89%	-18.46%	174.47%	-20.12%	-43.27%	-168.98%	-10.38%	5.18%	-2.99%	1.02%	0.00%
NOPAT Q/Q Growth	15.75%	-26.64%	170.50%	-12.65%	-34.98%	-169.94%	-14.58%	5.12%	-2.99%	0.96%	0.00%
Net Income Q/Q Growth	15.93%	-26.00%	185.97%	-11.21%	-28.21%	-1,629.95%	5.66%	-1.46%	-1.33%	-0.62%	0.00%
EPS Q/Q Growth	14.57%	-24.67%	185.85%	-14.29%	-28.48%	-2,685.71%	5.31%	-0.68%	-1.11%	-0.37%	0.00%
Operating Cash Flow Q/Q Growth	3.45%	0.70%	876.71%	-49.78%	-21.70%	-77.20%	-8.63%	6.08%	-6.25%	12.45%	16.87%
Free Cash Flow Firm Q/Q Growth	2.67%	-2.31%	248.96%	-79.98%	-31.77%	-210.45%	-30.26%	10.07%	-10.08%	1.66%	0.00%
Invested Capital Q/Q Growth	65.95%	14.26%	-70.46%	4.87%	5.83%	-19.88%	3.78%	-6.03%	3.46%	3.47%	0.00%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	79.18%	38.57%	26.55%	43.53%	17.38%	-30.65%	-107.29%	-138.83%	-173.84%	-178.04%	-122.80%
Operating Margin	77.17%	34.94%	23.94%	42.75%	17.90%	-34.00%	-112.88%	-143.74%	-173.23%	-179.92%	-130.65%
EBIT Margin	77.38%	34.97%	23.79%	42.72%	17.90%	-33.88%	-112.90%	-143.64%	-173.23%	-179.82%	-130.60%
Profit (Net Income) Margin	49.10%	24.55%	17.23%	34.82%	22.60%	-29.53%	-81.38%	-141.31%	-168.95%	-171.58%	-125.36%
Tax Burden Percent	62.96%	66.54%	65.72%	77.27%	101.81%	103.28%	73.43%	99.65%	102.15%	98.52%	98.01%
Interest Burden Percent	100.77%	105.47%	110.19%	105.50%	124.01%	84.40%	98.16%	98.73%	95.47%	96.85%	97.94%
Effective Tax Rate	37.04%	33.46%	34.28%	22.73%	-1.81%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	367.36%	77.11%	93.82%	181.25%	57.73%	-59.90%	-186.87%	-203.38%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	366.88%	76.60%	93.25%	180.06%	55.26%	-58.19%	-186.27%	-192.34%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	-326.31%	-68.54%	-87.62%	-160.55%	-46.89%	52.02%	168.39%	169.59%	0.00%	0.00%	0.00%
Return on Equity (ROE)	41.06%	8.56%	6.20%	20.70%	10.84%	-7.88%	-18.48%	-33.79%	-49.74%	-67.17%	-84.63%
Cash Return on Invested Capital (CROIC)	321.99%	73.28%	208.44%	20.35%	67.48%	-6.58%	-212.97%	-185.65%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	62.03%	11.71%	8.05%	23.83%	8.13%	-8.50%	-23.70%	-30.40%	-32.76%	-28.99%	-25.95%
Return on Assets (ROA)	39.36%	8.22%	5.83%	19.42%	10.26%	-7.41%	-17.08%	-29.91%	-31.95%	-27.67%	-24.91%
Return on Common Equity (ROCE)	41.06%	8.56%	6.20%	20.70%	10.84%	-7.88%	-18.48%	-33.79%	-49.74%	-67.17%	-84.63%
Return on Equity Simple (ROE_SIMPLE)	33.45%	8.03%	5.87%	18.28%	10.03%	-7.94%	-19.78%	-37.89%	0.00%	-90.09%	0.00%
Net Operating Profit after Tax (NOPAT)	78	21	16	68	37	-29	-77	-87	-96	-85	-60
NOPAT Margin	48.59%	23.25%	15.73%	33.03%	18.23%	-23.80%	-79.01%	-100.62%	-121.26%	-125.95%	-91.46%
Net Nonoperating Expense Percent (NNEP)	0.48%	0.51%	0.57%	1.19%	2.47%	-1.71%	-0.59%	-11.04%	-11.58%	-9.98%	-10.12%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-	-44.31%	-	-92.32%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	8.42%	19.22%	20.18%	11.34%	12.79%	22.34%	33.52%	52.79%	66.77%	85.53%	67.25%
R&D to Revenue	14.41%	45.84%	55.88%	45.91%	69.31%	111.66%	179.36%	190.95%	206.46%	194.39%	163.40%
Operating Expenses to Revenue	22.83%	65.06%	76.06%	57.25%	82.10%	134.00%	212.88%	243.74%	273.23%	279.92%	230.65%
Earnings before Interest and Taxes (EBIT)	124	31	24	88	37	-41	-110	-124	-137	-122	-85
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	127	34	27	90	36	-38	-104	-120	-138	-120	-80
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.86	1.88	2.96	4.21	2.56	2.02	2.88	3.35	1.09	1.70	3.95
Price to Tangible Book Value (P/TBV)	2.86	1.88	2.96	4.21	2.56	2.02	2.88	3.35	1.09	1.70	3.95
Price to Revenue (P/Rev)	4.20	5.74	8.69	8.01	5.76	7.50	11.83	12.48	2.97	3.25	3.92
Price to Earnings (P/E)	8.56	23.38	50.45	23.01	25.49	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	11.68%	4.28%	1.98%	4.35%	3.92%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	17.88	9.75	81.47	19.59	12.69	14.00	17.15	20.50	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	2.90	2.99	5.83	6.44	3.81	4.08	8.20	9.24	0.00	0.00	1.03
Enterprise Value to EBITDA (EV/EBITDA)	3.67	7.77	21.97	14.80	21.94	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	3.75	8.56	24.52	15.08	21.29	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	5.97	12.88	37.07	19.50	20.91	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	6.09	7.38	11.39	45.55	10.95	70.49	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	6.81	13.55	16.69	173.71	17.89	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.89	-0.89	-0.94	-0.89	-0.85	-0.89	-0.90	-0.88	-1.21	-1.79	-2.26
Leverage Ratio	1.04	1.04	1.06	1.07	1.06	1.06	1.08	1.13	1.56	2.43	3.40
Compound Leverage Factor	1.05	1.10	1.17	1.12	1.31	0.90	1.06	1.12	1.49	2.35	3.33
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	44.33	28.57	23.03	51.01	28.02	19.40	17.83	11.70	0.07	-0.78	-1.41
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	25.45	29.43	11.33	23.74	17.77	18.08	8.82	10.45	6.73	5.21	4.21
Quick Ratio	24.00	28.26	11.17	23.46	17.10	16.98	7.40	9.04	6.03	4.43	4.03
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	69	20	36	7.66	44	-3.20	-87	-79	96	-118	-56
Operating Cash Flow to CapEx	3,282.23%	755.78%	2,101.08%	980.21%	1,318.41%	490.52%	-9,332.80%	-3,989.74%	-1,138.82%	-438.85%	-149.44%
Free Cash Flow to Firm to Interest Expense	8,564.26	0.00	0.00	0.00	0.00	0.00	0.00	0.00	18.64	-10.82	-7.24
Operating Cash Flow to Interest Expense	9,584.13	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-20.04	-7.20	-2.51
Operating Cash Flow Less CapEx to Interest Expense	9,292.13	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-21.80	-8.84	-4.19
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.80	0.33	0.34	0.56	0.45	0.25	0.21	0.21	0.19	0.16	0.20
Accounts Receivable Turnover	15.92	6.18	8.77	5.31	3.46	3.27	4.12	3.93	5.48	8.86	9.66
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	41.85	12.71	12.81	25.16	21.26	12.55	13.35	14.22	8.76	3.03	1.92
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	22.93	59.06	41.63	68.73	105.41	111.47	88.49	92.97	66.66	41.18	37.79
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	22.93	59.06	41.63	68.73	105.41	111.47	88.49	92.97	66.66	41.18	37.79
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	26	27	7.36	68	62	36	46	39	-153	-120	-124
Invested Capital Turnover	7.56	3.32	5.96	5.49	3.17	2.52	2.37	2.02	-1.39	-0.50	-0.54
Increase / (Decrease) in Invested Capital	9.66	1.02	-20	61	-6.32	-26	11	-7.55	-192	33	-4.17
Enterprise Value (EV)	467	264	600	1,331	782	500	796	796	-135	-29	67
Market Capitalization	676	507	893	1,656	1,182	919	1,148	1,075	235	220	256
Book Value per Share	$12.62	$14.18	$15.80	$20.32	$23.50	$22.70	$19.76	$15.50	$10.29	$6.08	$3.03
Tangible Book Value per Share	$12.62	$14.18	$15.80	$20.32	$23.50	$22.70	$19.76	$15.50	$10.29	$6.08	$3.03
Total Capital	236	270	302	394	462	456	399	321	217	129	65
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-209	-242	-294	-325	-400	-419	-352	-279	-370	-249	-189
Capital Expenditures (CapEx)	2.34	4.74	2.51	2.98	5.42	1.45	0.75	2.13	9.06	18	13
Debt-free, Cash-free Net Working Capital (DFCFNWC)	19	14	-6.83	56	44	26	39	33	-9.91	-6.48	-33
Debt-free Net Working Capital (DFNWC)	164	224	217	364	379	413	283	282	360	242	156
Net Working Capital (NWC)	164	224	217	364	379	413	283	282	360	242	156
Net Nonoperating Expense (NNE)	-0.82	-1.14	-1.53	-3.70	-8.98	7.02	2.29	35	38	31	22
Net Nonoperating Obligations (NNO)	-210	-243	-294	-326	-401	-420	-353	-282	-370	-249	-189
Total Depreciation and Amortization (D&A)	2.88	3.17	2.84	1.68	-1.08	3.95	5.45	4.14	-0.49	1.20	5.09
Debt-free, Cash-free Net Working Capital to Revenue	11.64%	16.07%	-6.65%	26.93%	21.44%	21.25%	40.02%	37.90%	-12.51%	-9.58%	-50.64%
Debt-free Net Working Capital to Revenue	101.90%	254.08%	210.90%	176.34%	184.82%	336.96%	291.37%	327.17%	454.53%	358.27%	238.47%
Net Working Capital to Revenue	101.90%	254.08%	210.90%	176.34%	184.82%	336.96%	291.37%	327.17%	454.53%	358.27%	238.47%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$4.23	$1.14	$0.93	$3.74	$2.37	($1.81)	($3.92)	($5.91)	($6.38)	($5.48)	($3.84)
Adjusted Weighted Average Basic Shares Outstanding	18.67M	18.93M	19.07M	19.26M	19.58M	19.94M	20.17M	20.60M	20.97M	21.16M	21.34M
Adjusted Diluted Earnings per Share	$4.09	$1.13	$0.91	$3.48	$2.21	($1.81)	($3.92)	($5.91)	($6.38)	($5.48)	($3.84)
Adjusted Weighted Average Diluted Shares Outstanding	19.29M	19.22M	19.41M	20.65M	20.97M	19.94M	20.17M	20.60M	20.97M	21.16M	21.34M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	18.80M	19.04M	19.13M	19.42M	19.73M	20.08M	20.32M	20.80M	21.06M	21.19M	28.86M
Normalized Net Operating Profit after Tax (NOPAT)	78	21	16	68	26	-29	-77	-87	-96	-85	-60
Normalized NOPAT Margin	48.59%	23.25%	15.73%	33.03%	12.53%	-23.80%	-79.01%	-100.62%	-121.26%	-125.95%	-91.46%
Pre Tax Income Margin	77.98%	36.89%	26.21%	45.07%	22.20%	-28.59%	-110.82%	-141.82%	-165.39%	-174.15%	-127.90%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	15,561.88	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-26.65	-11.12	-11.11
NOPAT to Interest Expense	9,771.13	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-18.66	-7.79	-7.78
EBIT Less CapEx to Interest Expense	15,269.88	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-28.41	-12.76	-12.79
NOPAT Less CapEx to Interest Expense	9,479.13	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-20.42	-9.43	-9.46
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Enanta Pharmaceuticals' official financial filings.

Metric	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026	Q2 2026
Period end date	9/30/2023	12/31/2024	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	12/31/2025	3/31/2026
DEI Shares Outstanding	21,055,392.00	21,055,392.00	21,155,983.00	21,179,400.00	-	21,194,326.00	21,332,544.00	21,376,581.00	28,862,601.00	29,019,344.00
DEI Adjusted Shares Outstanding	21,055,392.00	21,055,392.00	21,155,983.00	21,179,400.00	-	21,194,326.00	21,332,544.00	21,376,581.00	28,862,601.00	29,019,344.00
DEI Earnings Per Adjusted Shares Outstanding	-1.33	-1.59	-1.47	-1.07	-	-1.05	-1.06	-0.85	-0.41	-0.45
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-6.82%	-28.09%	-4.16%	-4.88%	-22.84%	0.00%	-12.48%	1.91%	9.76%	14.96%
EBITDA Growth	-15.51%	26.20%	19.53%	36.48%	-0.50%	0.00%	29.93%	25.84%	54.58%	54.06%
EBIT Growth	-14.72%	21.56%	16.95%	34.12%	3.79%	0.00%	25.15%	21.88%	52.20%	51.68%
NOPAT Growth	-14.72%	21.56%	16.95%	34.12%	3.79%	0.00%	25.15%	21.88%	52.20%	51.68%
Net Income Growth	-6.68%	23.10%	17.26%	42.00%	-2.55%	0.00%	27.32%	19.43%	46.44%	42.19%
EPS Growth	-5.51%	24.46%	17.88%	42.47%	-1.49%	0.00%	27.89%	20.56%	60.00%	57.55%
Operating Cash Flow Growth	-39.06%	52.86%	-107.51%	54.01%	51.86%	32.76%	52.84%	218.48%	30.37%	46.95%
Free Cash Flow Firm Growth	1,596.56%	457.47%	578.96%	-129.43%	-131.76%	-184.43%	-135.69%	75.28%	188.09%	104.13%
Invested Capital Growth	-494.28%	-290.20%	-442.98%	21.66%	21.67%	0.00%	27.74%	-0.44%	0.00%	-10.61%
Revenue Q/Q Growth	0.21%	-10.42%	0.56%	5.38%	-18.72%	16.10%	-11.99%	22.70%	0.00%	-7.82%
EBITDA Q/Q Growth	18.89%	27.62%	-45.85%	25.82%	-28.33%	27.98%	-2.21%	27.96%	0.00%	-3.38%
EBIT Q/Q Growth	15.48%	24.13%	-39.18%	26.19%	-23.44%	21.14%	-4.18%	22.97%	0.00%	-5.32%
NOPAT Q/Q Growth	15.48%	24.13%	-39.18%	26.19%	-23.44%	21.14%	-4.18%	22.97%	0.00%	-5.32%
Net Income Q/Q Growth	28.05%	20.70%	-39.78%	27.28%	-27.21%	22.67%	-1.59%	19.38%	0.00%	-9.66%
EPS Q/Q Growth	27.96%	21.64%	-40.00%	27.21%	-27.10%	22.79%	-0.95%	19.81%	0.00%	-7.14%
Operating Cash Flow Q/Q Growth	32.76%	22.22%	-70.23%	48.34%	29.61%	-61.55%	19.72%	0.00%	-80.29%	38.83%
Free Cash Flow Firm Q/Q Growth	-2.29%	-15.17%	7.65%	-132.99%	-5.45%	-125.47%	54.50%	77.15%	0.00%	-97.87%
Invested Capital Q/Q Growth	3.46%	31.14%	-30.98%	10.04%	3.47%	100.00%	0.00%	-25.04%	0.00%	4.24%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	-160.71%	-129.85%	-188.34%	-132.58%	-209.33%	-129.85%	-150.80%	-96.48%	-53.74%	-60.27%
Operating Margin	-163.90%	-138.82%	-192.13%	-134.58%	-204.38%	-138.82%	-164.32%	-103.16%	-60.45%	-69.07%
EBIT Margin	-163.90%	-138.82%	-192.13%	-134.58%	-204.38%	-138.82%	-164.32%	-103.16%	-60.45%	-69.07%
Profit (Net Income) Margin	-148.46%	-131.43%	-182.70%	-126.08%	-197.32%	-131.43%	-151.71%	-99.68%	-64.13%	-76.29%
Tax Burden Percent	95.22%	98.17%	98.85%	98.29%	98.76%	98.17%	94.55%	100.16%	100.20%	100.05%
Interest Burden Percent	95.12%	96.44%	96.20%	95.32%	97.76%	96.44%	97.64%	96.47%	105.87%	110.39%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-49.74%	-61.61%	-55.39%	-59.64%	-67.17%	0.00%	-82.83%	0.00%	-56.51%	-59.00%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-30.99%	-28.95%	-37.30%	-21.67%	-32.95%	0.00%	-29.23%	0.00%	-12.29%	-14.99%
Return on Assets (ROA)	-28.07%	-27.40%	-35.47%	-20.30%	-31.82%	0.00%	-26.99%	0.00%	-13.04%	-16.56%
Return on Common Equity (ROCE)	-49.74%	-61.61%	-55.39%	-59.64%	-67.17%	0.00%	-82.83%	0.00%	-56.51%	-59.00%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-113.69%	-72.61%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-22	-16	-23	-17	-21	-16	-17	-13	-7.88	-8.30
NOPAT Margin	-114.73%	-97.18%	-134.49%	-94.20%	-143.07%	-97.18%	-115.03%	-72.21%	-42.32%	-48.35%
Net Nonoperating Expense Percent (NNEP)	-1.96%	-2.51%	-3.08%	-1.71%	-2.56%	0.00%	-2.20%	-2.11%	-3.36%	-2.28%
Return On Investment Capital (ROIC_SIMPLE)	-10.02%	-14.74%	-13.81%	-11.37%	-	-	-18.36%	-16.68%	-6.22%	-7.12%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	72.87%	75.75%	83.47%	74.64%	93.67%	75.75%	76.30%	54.59%	48.40%	55.76%
R&D to Revenue	191.04%	163.08%	208.66%	159.94%	210.71%	163.08%	188.03%	148.57%	112.05%	113.31%
Operating Expenses to Revenue	263.90%	238.82%	292.13%	234.58%	304.38%	238.82%	264.32%	203.16%	160.45%	169.07%
Earnings before Interest and Taxes (EBIT)	-31	-24	-33	-24	-30	-24	-25	-19	-11	-12
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-30	-22	-32	-24	-31	-22	-23	-18	-10	-10
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.09	1.09	2.22	1.84	1.70	0.00	1.26	2.04	3.60	3.14
Price to Tangible Book Value (P/TBV)	1.09	1.09	2.22	1.84	1.70	0.00	1.26	2.04	3.60	3.14
Price to Revenue (P/Rev)	2.97	1.68	5.14	3.82	3.25	1.83	1.80	0.00	6.80	5.30
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.96	0.02	0.00	0.00	0.00	0.00	3.18	2.02
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.75	0.00	0.00	0.00	0.00	0.00	3.32	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-1.21	-1.12	-1.22	-1.73	-1.79	0.00	-1.92	-2.09	-1.91	-2.00
Leverage Ratio	1.56	1.69	1.70	2.31	2.43	0.00	2.84	3.07	2.60	3.03
Compound Leverage Factor	1.48	1.63	1.63	2.20	2.37	0.00	2.77	2.96	2.76	3.35
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	0.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	0.83	-0.34	0.75	0.29	0.02	0.00	-0.60	0.00	0.23	-0.20
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	6.73	5.47	6.43	4.92	5.21	0.00	5.29	5.00	4.44	3.84
Quick Ratio	6.03	4.58	5.64	4.09	4.43	0.00	4.36	4.77	4.35	3.69
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	170	144	156	-51	-54	-122	-55	-13	107	2.29
Operating Cash Flow to CapEx	-1,579.09%	-192.12%	-1,714.69%	-225.85%	-116.19%	-192.12%	-531.44%	11,294.19%	-8,181.12%	-47,706.67%
Free Cash Flow to Firm to Interest Expense	54.05	73.63	60.68	-21.78	-20.96	-62.16	-32.38	-7.84	34.85	0.69
Operating Cash Flow to Interest Expense	-6.86	-8.56	-11.16	-6.27	-4.03	-8.56	-7.87	10.82	-3.79	-2.16
Operating Cash Flow Less CapEx to Interest Expense	-7.29	-13.02	-11.81	-9.05	-7.50	-13.02	-9.35	10.72	-3.84	-2.16
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.19	0.21	0.19	0.16	0.16	0.00	0.18	0.00	0.20	0.22
Accounts Receivable Turnover	5.48	4.79	5.62	5.32	8.86	0.00	9.01	0.00	7.89	9.48
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	8.76	3.15	5.42	3.88	3.03	0.00	2.47	0.00	1.95	1.96
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	66.66	76.20	64.91	68.65	41.18	0.00	40.53	0.00	46.28	38.50
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	66.66	76.20	64.91	68.65	41.18	0.00	40.53	0.00	46.28	38.50
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	-153	-105	-138	-124	-120	0.00	-100	-125	-115	-110
Invested Capital Turnover	-1.39	-2.90	-1.47	-0.51	-0.50	0.00	-0.55	0.00	-1.16	-0.66
Increase / (Decrease) in Invested Capital	-192	-161	-178	34	33	105	38	-0.54	-115	-11
Enterprise Value (EV)	-135	-95	69	1.49	-29	0.00	-76	-43	213	140
Market Capitalization	235	122	369	275	220	122	118	162	455	367
Book Value per Share	$10.29	$5.28	$7.85	$7.03	$6.08	$0.00	$4.38	$3.71	$4.39	$4.02
Tangible Book Value per Share	$10.29	$5.28	$7.85	$7.03	$6.08	$0.00	$4.38	$3.71	$4.39	$4.02
Total Capital	217	112	166	149	129	0.00	94	79	127	117
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-370	-217	-300	-273	-249	0.00	-193	-204	-242	-227
Capital Expenditures (CapEx)	1.37	8.75	1.67	6.54	8.95	8.75	2.54	0.16	0.14	0.02
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-9.91	1.80	-3.89	-2.34	-6.48	0.00	3.54	-26	-32	-32
Debt-free Net Working Capital (DFNWC)	360	219	296	228	242	0.00	197	178	154	132
Net Working Capital (NWC)	360	219	296	228	242	0.00	197	178	154	132
Net Nonoperating Expense (NNE)	6.39	5.81	8.22	5.73	7.93	5.81	5.48	5.03	4.06	4.79
Net Nonoperating Obligations (NNO)	-370	-217	-304	-273	-249	0.00	-193	-204	-242	-227
Total Depreciation and Amortization (D&A)	0.61	1.52	0.65	0.36	-0.72	1.52	2.02	1.22	1.25	1.51
Debt-free, Cash-free Net Working Capital to Revenue	-12.51%	2.47%	-5.41%	-3.25%	-9.58%	0.00%	5.40%	0.00%	-47.62%	-45.95%
Debt-free Net Working Capital to Revenue	454.53%	301.88%	412.63%	317.33%	358.27%	0.00%	300.60%	0.00%	229.85%	190.67%
Net Working Capital to Revenue	454.53%	301.88%	412.63%	317.33%	358.27%	0.00%	300.60%	0.00%	229.85%	190.67%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($1.34)	($1.05)	($1.47)	($1.07)	($1.36)	$0.00	($1.06)	($0.85)	($0.42)	($0.45)
Adjusted Weighted Average Basic Shares Outstanding	20.97M	21.24M	21.17M	21.18M	21.16M	0.00	21.36M	21.38M	28.75M	29.04M
Adjusted Diluted Earnings per Share	($1.34)	($1.05)	($1.47)	($1.07)	($1.36)	$0.00	($1.06)	($0.85)	($0.42)	($0.45)
Adjusted Weighted Average Diluted Shares Outstanding	20.97M	21.24M	21.17M	21.18M	21.16M	0.00	21.36M	21.38M	28.75M	29.04M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	21.06M	21.33M	21.18M	21.19M	21.19M	0.00	21.38M	21.38M	29.02M	29.08M
Normalized Net Operating Profit after Tax (NOPAT)	-22	-16	-23	-17	-21	-16	-17	-13	-7.88	-8.30
Normalized NOPAT Margin	-114.73%	-97.18%	-134.49%	-94.20%	-143.07%	-97.18%	-115.03%	-72.21%	-42.32%	-48.35%
Pre Tax Income Margin	-155.91%	-133.89%	-184.82%	-128.28%	-199.81%	-133.89%	-160.45%	-99.52%	-64.00%	-76.25%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-9.85	-12.00	-12.78	-10.27	-11.57	-12.00	-14.31	-11.68	-3.65	-3.57
NOPAT to Interest Expense	-6.89	-8.40	-8.95	-7.19	-8.10	-8.40	-10.02	-8.17	-2.56	-2.50
EBIT Less CapEx to Interest Expense	-10.28	-16.46	-13.44	-13.05	-15.03	-16.46	-15.79	-11.77	-3.70	-3.58
NOPAT Less CapEx to Interest Expense	-7.33	-12.86	-9.60	-9.97	-11.56	-12.86	-11.50	-8.27	-2.60	-2.51
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials Breakdown Chart

Key Financial Trends

Enanta Pharmaceuticals (NASDAQ: ENTA) continues to operate with a strong cash and investment cushion, but its latest quarterly results show ongoing losses and pressure from heavy R&D spending.

For Q2 2026, Enanta posted revenue of $17.2 million and a net loss of $13.1 million, or -$0.45 per share. Revenue was slightly below Q1 2026’s $18.6 million, while the company remained unprofitable due to operating expenses that exceeded gross profit.

The balance sheet still looks relatively solid from a liquidity standpoint. As of March 31, 2026, Enanta held $34.9 million in cash, $128.8 million in short-term investments, and $63.2 million in long-term investments. That gives the company substantial resources to fund operations, even though it is burning cash.

Key positives

Large liquidity position, with about $227 million combined in cash and investments as of Q2 2026.
Quarterly operating cash burn improved versus some prior periods, with Q2 2026 operating cash flow of -$7.2 million compared with -$11.7 million in Q1 2026.
Investment income helped offset losses, with $2.1 million of interest and investment income in Q2 2026.
Q2 2026 revenue of $17.2 million remained in line with recent quarters, suggesting the top line has not collapsed.
The company has maintained a sizable asset base, with $314.7 million in total assets in Q2 2026.

Neutral items

Revenue has been relatively stable over the last several quarters, generally ranging from the mid-teens to high-teens millions.
Shares outstanding increased sharply in early 2026, with weighted average basic shares rising to 29.0 million in Q2 from 21.1 million a year earlier, which can dilute per-share results.
The company’s noncurrent liabilities remain large at $151.7 million, which investors should monitor closely.

Key negatives

Enanta remains unprofitable, posting a Q2 2026 net loss of $13.1 million and Q1 2026 net loss of $11.9 million.
Operating losses continue to be significant, with Q2 2026 operating income of -$11.9 million.
Research & development spending remains very high at $19.4 million in Q2 2026, keeping pressure on margins.
Interest expense is still meaningful at $3.3 million in Q2 2026, which adds to the burden of ongoing losses.
Cash and equivalents declined from $37.4 million in Q1 2026 to $34.9 million in Q2 2026, while investments also fell, reflecting continued use of capital.
Compared with late 2024 and early 2025, total equity has fallen substantially, signaling shareholder value erosion over time.
The company has not yet shown a clear path to sustained profitability, with losses persisting across the last four years of available quarterly data.

Bottom line: Enanta has enough liquidity to keep operating for now, but the long-term story still hinges on whether it can convert its pipeline and revenue base into durable profitability. For retail investors, the main question is not near-term solvency; it is whether management can reduce losses and eventually improve returns on its sizable cash and investment base.

07/05/26 06:27 PM ETAI Generated. May Contain Errors.

Enanta Pharmaceuticals Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Enanta Pharmaceuticals' fiscal year ends in September. Their fiscal year 2025 ended on September 30, 2025.

Enanta Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of -$81.89 million in 2025, falling from $78.99 million in 2015. The previous period was -$116.05 million in 2024. Find out what analysts predict for Enanta Pharmaceuticals in the coming months.

Enanta Pharmaceuticals' total operating income in 2025 was -$85.35 million, based on the following breakdown:

Total Gross Profit: $65.32 million
Total Operating Expenses: $150.67 million

Over the last 10 years, Enanta Pharmaceuticals' total revenue changed from $160.88 million in 2015 to $65.32 million in 2025, a change of -59.4%.

Enanta Pharmaceuticals' total liabilities were at $216.02 million at the end of 2025, a 12.8% decrease from 2024, and a 2,091.7% increase since 2015.

In the past 10 years, Enanta Pharmaceuticals' cash and equivalents has ranged from $16.58 million in 2016 to $87.13 million in 2020, and is currently $32.30 million as of their latest financial filing in 2025.

Over the last 10 years, Enanta Pharmaceuticals' book value per share changed from 12.62 in 2015 to 3.03 in 2025, a change of -76.0%.

Related Companies

Financial statements for NASDAQ:ENTA last updated on 7/2/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Enanta Pharmaceuticals (ENTA) Financials

Financials Breakdown Chart

Key Financial Trends

Enanta Pharmaceuticals Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Enanta Pharmaceuticals (ENTA) Financials

Annual Income Statements for Enanta Pharmaceuticals

Quarterly Income Statements for Enanta Pharmaceuticals

Annual Cash Flow Statements for Enanta Pharmaceuticals

Quarterly Cash Flow Statements for Enanta Pharmaceuticals

Annual Balance Sheets for Enanta Pharmaceuticals

Quarterly Balance Sheets for Enanta Pharmaceuticals

Annual Metrics And Ratios for Enanta Pharmaceuticals

Quarterly Metrics And Ratios for Enanta Pharmaceuticals

Financials Breakdown Chart

Key Financial Trends

Enanta Pharmaceuticals Financials - Frequently Asked Questions

When does Enanta Pharmaceuticals' financial year end?

How has Enanta Pharmaceuticals' net income changed over the last 10 years?

What is Enanta Pharmaceuticals' operating income?

How has Enanta Pharmaceuticals' revenue changed over the last 10 years?

How much debt does Enanta Pharmaceuticals have?

How much cash does Enanta Pharmaceuticals have?

How has Enanta Pharmaceuticals' book value per share changed over the last 10 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools